Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis - 12/09/19
, Jacob P. Thyssen, MD, PhD, DMScAbstract |
Background |
Factors that are associated with patient-reported importance of obtaining complete or almost complete clearance of psoriasis and atopic dermatitis (AD) are unknown.
Objectives |
To investigate the importance of and factors associated with obtaining complete or almost complete clearance of psoriasis or AD.
Methods |
A cross-sectional study of 4016 and 3842 adults with psoriasis and AD.
Results |
Patients with AD reported significantly greater importance of almost complete or complete skin clearance compared with patients with psoriasis. For both patient groups, almost complete was more important that complete skin clearance. Increasing disease severity and itch and skin pain were significantly associated with perceived importance of skin clearance for patients with both diseases. AD and psoriasis located on the face or neck and psoriasis located on the palms, soles, or genitals were significantly associated with patient-perceived importance of almost complete skin clearance. Only 7% and 27% of patients with severe AD and psoriasis, respectively, were currently receiving a systemic therapy.
Limitations |
Specific reasons for infrequent use of systemic treatments was not examined.
Conclusion |
Patients with psoriasis or AD expressed a strong request for almost complete or complete skin clearance. Patient education and effective therapies should be used to reduce disease severity.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, Danish Skin Cohort, epidemiology, psoriasis, treatment goals
Abbreviations used : AD, BSA, DLQI, NRS, PO-SCORAD
Plan
| Funding sources: Supported by funding from the Danish Psoriasis Foundation (Psoriasisforeningen). |
|
| Disclosure: Dr Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as a consultant and/or speaker from AbbVie; Almirall; Leo Pharma; Samsung Bioepis Co, Ltd; Pfizer; Eli Lilly and Co; Novartis; Galderma; Dermavant; Bristol-Myers Squibb; and Janssen Pharmaceuticals. Dr Thyssen has attended advisory boards for Sanofi-Genzyme, Union Therapeutics, and Eli Lilly and Co; received speaker honoraria from LEO Pharma and Sanofi-Genzyme; and been an investigator for Sanofi-Genzyme, Eli Lilly and Co, LEO Pharma, and AbbVie. |
|
| Reprints not available from the authors. |
Vol 81 - N° 4
P. 943-949 - octobre 2019 Retour au numéro
Article précédent
- All-cause mortality among patients with hidradenitis suppurativa: A population-based cohort study in the United States
- Sarah Reddy, Andrew Strunk, Amit Garg
- Localization and age distribution of telangiectases in children and adolescents with hereditary hemorrhagic telangiectasia: A retrospective cohort study
- Cristian D. Gonzalez, Sarah D. Cipriano, Christina A. Topham, David A. Stevenson, Kevin J. Whitehead, Sheryll Vanderhooft, Angela P. Presson, Jamie McDonald
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?